Cambridge NeuroScience Inc said Thursday that Boehringer Ingelheim, a privately held German pharmaceutical group, plans to buy a 17-percent stake in the company.
Boehringer is buying 1,237,624 shares of Cambridge NeuroScience common stock at a price of $8.08 a share.
The $10 million transaction is expected to take place in the next several weeks.
The two companies teamed up last year to develop a drug to treat patients who have suffered strokes and traumatic brain injuries.